Lipid Nanoparticles as Carriers for RNAi against Viral Infections: Current Status and Future Perspectives

Table 4

Clinical trials evolving the application of RNAi in the treatment of viral infections.

Clinical candidate	Targeting virus	RNAi molecule	Clinical phase	Company	Reference
ALN-RSV01	RSV	siRNA	IIb	Alnylam Pharmaceuticals Inc.	[52]
Miravirsen, SPC3649	HCV	antimiRNA	IIa	Santaris Pharma A/S	[53, 54]
TT-034	HCV	shRNA	I/IIa	Benitec Biopharma Ltd.	[55]
ARC-520	HBV	siRNA	II	Arrowhead Research Corporation	[56]
CCR5 negative cells (generated ex vivo)	HIV	shRNA	I/II	Calimmune and Benitec Biopharma Ltd.	[57]
TKM-Ebola	Ebola virus	siRNAs	I	Tekmira Pharmaceuticals	[58]

CCR5: chemokine receptor 5; RSV: respiratory syncytial virus; HCV: hepatitis C virus; HBV: hepatitis B virus; HIV: human immunodeficiency virus; siRNA: short interfering RNA; miRNA: microRNA; shRNA: short hairpin RNA.